Cadila Healthcare jumps 9% on USFDA nod for hypertension drug
Stock of Cadila Healthcare soared
9 per cent today after the drugmaker announced that Zydus
Cadila received final approval from the USFDA to market
candesartan cilexetil tablets used for treatment of
The scrip rose 8.95 per cent to an intra-day high of Rs
503.90 on the BSE. It had opened at Rs 465.85.
A similar movement was witnessed on the NSE where the
stock moved 8.93 per cent higher to Rs 504 during the intra-
Cadila Healthcare is part of Zydus Cadila.
In a regulatory filing to exchanges, Cadila Healthcare
today said Zydus Cadila has received the final approval from
the US Food and Drug Administration (USFDA) to market
candesartan cilexetil tablets in strength of 4 mg, 8 mg, 16 mg
and 32 mg.
The company will manufacture the drug at its formulation
manufacturing facility in Moraiya in Ahmedabad.
It has more than 140 approvals and has so far filed over
300 abbreviated new drug applications (ANDAs) since it
commenced filings in 2003-04.
At 1302 hours, Cadila Healthcare is trading at Rs 497.35
on the BSE, up 7.66 per cent from the previous close. The
stock was up 7.9 per cent at Rs 499.20 on the NSE.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.